BillionToOne, Inc. (BLLN)
Health Care ยท Services-Medical Laboratories
BillionToOne, Inc. (BLLN) is listed on Nasdaq, where its shares have traded since November 6, 2025. SentiSense covers BillionToOne, Inc. in the Health Care sector, and its Standard Industrial Classification is Services-Medical Laboratories. Oguzhan Atay is its chief executive officer. The company reports 713 employees, and its corporate website is www.billiontoone.com.
About BillionToOne, Inc.
BillionToOne Inc is a molecular diagnostics company. It offers a portfolio of ultrasensitive tests covering prenatal genetic testing, cancer therapy selection, and response monitoring, which are based on its Quantitative Counting Templates (QCT) molecular counting platform. The company's product portfolio comprises UNITY, a portfolio of prenatal testing products that can conduct fetal risk analysis without requiring a paternal sample; Northstar Select, a ultrasensitive liquid biopsy test that provides insights into appropriate therapies for stage III or IV cancer patients; and Northstar Response, a tissue-free, pan-cancer, liquid biopsy test that measures several genomic loci uniquely methylated in cancer to provide insight into dynamic changes in therapy response.
Institutional ownership
In 13F filings for the quarter ended June 30, 2026, 152 institutions reported holding BLLN, with 15.3 million shares worth $1.8 billion in aggregate. The largest reported holders were Adams Street Partners, Vanguard and T. Rowe Price. Of the 5 largest reported holders, 3 added shares, 1 reduced its position and 1 held its position unchanged during the quarter.
More on BLLN
- BLLN sentiment: whether news and social coverage of BillionToOne, Inc. leans bullish or bearish, and the stories driving it.
- BLLN ownership: all 152 reporting institutions, plus insider and congressional trades.
- BLLN financials: revenue, net income, operating margin and free cash flow by quarter and year.
SentiSense also tracks daily options readings for BillionToOne, Inc.: IV rank, put/call percentile, 25-delta skew and open-interest walls.
Frequently asked questions
What does BillionToOne, Inc. do?
BillionToOne Inc is a molecular diagnostics company. It offers a portfolio of ultrasensitive tests covering prenatal genetic testing, cancer therapy selection, and response monitoring, which are based on its Quantitative Counting Templates (QCT) molecular counting platform.
What sector is BLLN in?
SentiSense classifies BillionToOne, Inc. in the Health Care sector, and its Standard Industrial Classification is Services-Medical Laboratories.
Where does BLLN stock trade?
BillionToOne, Inc. (BLLN) is listed on Nasdaq, where its shares have traded since November 6, 2025.
Who is the CEO of BillionToOne, Inc.?
Oguzhan Atay is the chief executive officer of BillionToOne, Inc..